Wockhardt Limited (BOM:532300)
1,345.90
-17.25 (-1.27%)
At close: Jan 23, 2026
Wockhardt Revenue
Wockhardt had revenue of 7.82B INR in the quarter ending September 30, 2025, a decrease of -3.34%. This brings the company's revenue in the last twelve months to 30.07B, up 0.87% year-over-year. In the fiscal year ending March 31, 2025, Wockhardt had annual revenue of 30.35B with 7.24% growth.
Revenue (ttm)
30.07B
Revenue Growth
+0.87%
P/S Ratio
7.30
Revenue / Employee
13.10M
Employees
2,296
Market Cap
219.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 30.35B | 2.05B | 7.24% |
| Mar 31, 2024 | 28.30B | 1.73B | 6.51% |
| Mar 31, 2023 | 26.57B | -5.73B | -17.74% |
| Mar 31, 2022 | 32.30B | 5.22B | 19.28% |
| Mar 31, 2021 | 27.08B | -1.36B | -4.78% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 76.18B |
| Granules India | 48.42B |
| J. B. Chemicals & Pharmaceuticals | 41.93B |
| GlaxoSmithKline Pharmaceuticals | 37.09B |
| Caplin Point Laboratories | 20.42B |
| AstraZeneca Pharma India | 20.06B |
| Sanofi India | 19.33B |
| Viyash Scientific | 16.58B |